Skip NavigationSkip to Content
Return Return to Search Results

rhIL-15 and anti-PD-L1 combination therapy expands a CXCR3+PD1-/low CD8 T cell subset in SIV-infected rhesus macaques

  1. Author:
    Chen, Ping
    Chen, Hui
    Moussa, Maha
    Cheng, Jie
    Li, Tong
    Qin, Jing
    Lifson,Jeffrey
    Sneller, Michael C
    Krymskaya,Ludmila
    Godin, Steven
    Lane, H Clifford
    Catalfamo, Marta

  2. Author Address

    Department of Microbiology and Immunology. Georgetown University School of Medicine. Washington DC, USA., CMRS/Laboratory of Immunoregulation, NIAID, NIH, Bethesda, MD, USA., Biostatistics Research Branch, DCR, NIAID, NIH, Bethesda, MD, USA., AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc. Frederick National Laboratory, Frederick, MD, USA., Clinical Support 160;Laboratory, Leidos Biomedical Research, Inc. Frederick, MD, USA., Smithers Avanza Toxicology Services, Gaithersburg, MD, USA.,
    1. Year: 2020
    2. Date: Feb 15
    3. Epub Date: 2019 09 28
  2. Journal: The Journal of infectious diseases
    1. 221
    2. 4
    3. Pages: 523-533
  4. Type of Article: Article
  5. ISSN: 0022-1899
  1. Abstract:

    BACKGROUND: The PD1/PD-L1 pathway contributes to the pathogenesis of HIV/SIV infection and blockade of this pathway may have potential to restore immune function and promote viral control/elimination. In this study, we combined a checkpoint inhibitor anti-PD-L1 (Avelumab) and recombinant human IL-15 (rhIL-15) in SIV infected rhesus macaques (RM). METHODS: rhIL-15 was administered as continuous infusion in two cycles of ten days in the context of weekly administration of anti-PD-L1 (Avelumab) in SIV-infected RM receiving combination antiretroviral therapy (cART). Safety, immunological parameters and viral loads (VL) were monitored during the study. RESULTS: Administration of rhIL-15/anti-PD-L1 was safe and well tolerated. Treatment resulted in transient increases in proliferating (Ki67+) NK and CD8 T cells. In addition, treatment expanded a CXCR3+PD1-/low CD8 T cell subset with the ability to secrete cytokines. Despite these effects no changes in plasma viremia were observed after cART interruption. CONCLUSION: Expansion of the CXCR3+PD1-/low CD8 T cell subset with functional capacity and potential to traffic to sites of viral reservoirs in SIV-infected rhesus macaques, had no demonstrable effect on plasma viremia following cART interruption. © The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/infdis/jiz485
  3. PMID: 31562760
  4. View record in Web of Science®
  5. WOS: 000518533500008
  6. PII : 5575818

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel